Resources

  • Statement

    Incubate Executive Director John Stanford Statement in Response to the Centers for Medicare & Medicaid Services’ Devastating Final National Coverage Determination for Certain Alzheimer’s Treatments
    04.14.2022

    See Executive Director John Stanford's statement on CMS' Final NCD on Alzheimer's disease and how this will affect the future of biopharmaceutical investment.

  • Statement

    Incubate Letter in Opposition to MA S. 2774
    04.07.2022

    See Incubate's letter to the Massachusetts state legislature in opposition to S. 2774

  • Article

    To Spend Less on Healthcare, Invest in More Medicines
    04.05.2022

    Read John Stanford and JF Formela's op-ed on how we can lower health costs by spending more on drugs.

  • Statement

    Incubate Letter in Opposition to CT SB-13
    03.29.2022

    See Incubate's letter to Connecticut legislature opposing SB-13.

  • Statement

    Gaurav Gupta Comment on the Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
    02.10.2022

    Incubate Advisory Council member Gaurav Gupta's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

  • Statement

    Incubate Comment on the Proposed Decision Memo for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
    02.10.2022

    Executive Director John Stanford's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

  • Article

    CMS’s Devastating Blow to Seniors
    02.09.2022

    Read Incubate Advisory Council member Gaurav Gupta's op-ed on the CMS's decision to cover Alzheimer's drugs.

  • Statement

    Moonshot Statement
    02.02.2022

    Read Incubate Executive Director John Stanford's statement on President BIden's Moonshot initiative.

  • Article

    Investors Say Drug-Pricing Measure May Shift Incentives for Biotech Venture Funding
    12.02.2021

    A drug-pricing bill the House passed in November could affect which life-sciences startups venture-capital investors are likely to back.

  • Article

    House passage of Build Back Better gets mixed reaction
    11.22.2021

    As investors in biotechnology and pharmaceuticals, we're alarmed by the potential consequences of the drug-pricing measure included in the Build Back Better Act, which just passed the House.

  • Statement

    Leading Venture Capital Group Alarmed By Build Back Better Act’s Prescription Drug Provision
    11.19.2021

    John Stanford, Executive Director of Incubate, a coalition of America's early-stage life sciences investors, issued the following statement on congressional Democrats' passage of the Build Back Better Act

  • Policy Lab

    The Impact of Price Controls on Investment into Small Biotech Innovation
    11.11.2021

    This report attempts to understand the implications of price controls on the early-stage life science industry.